ADC Therapeutics (ADCT) Enterprise Value (2019 - 2026)

ADC Therapeutics has disclosed Enterprise Value across 8 years of filings, most recently posting -$231.0 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$231.0 million, down 18.65% year-over-year; the trailing twelve-month figure through Mar 2026 was -$231.0 million (down 18.65% YoY), and the FY2025 annual result was -$261.3 million, down 4.17% from the prior year.
• Enterprise Value came in at -$231.0 million for Q1 2026 at ADC Therapeutics, up from -$261.3 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$194.7 million in Q1 2025 to a low of -$326.4 million in Q4 2022.
• The 5-year median for Enterprise Value is -$261.3 million (2025), against an average of -$259.2 million.
• Across the five-year window, Enterprise Value soared 30.02% in 2022 and decreased 18.65% in 2026, its largest moves.
• ADC Therapeutics' Enterprise Value stood at -$326.4 million in 2022, then gained by 14.66% to -$278.6 million in 2023, then grew by 9.95% to -$250.9 million in 2024, then decreased by 4.17% to -$261.3 million in 2025, then advanced by 11.61% to -$231.0 million in 2026.
• The last three Enterprise Value figures came in at -$231.0 million (Q1 2026), -$261.3 million (Q4 2025), and -$234.7 million (Q3 2025), per Business Quant data.